Louise Frederika Kooij sold $3.1M of NAMS
Chief Accounting Officer at NewAmsterdam Pharma Co N.V.. 150,000 shares at an average of $20.37, traded Mar 4, 2025, filed Mar 5, 2025.
Score components
- +15RoleOfficer
- +25Trade size$3.1M at market
- +20Share of holdings soldSold 91% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-033927, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2025 | MOption exercise Ordinary Shares | +150,000 | - | - | 165,000 | Mar 5, 2025 |
| Mar 4, 2025 | SOpen-market sale Ordinary Shares | -150,000 | $20.37 | $3.1M | 15,000 | Mar 5, 2025 |
| Mar 4, 2025 | MOption exercise Option (right to buy)derivative | -150,000 | $0.00 | $0 | 18,073 | Mar 5, 2025 |
Related signals
Other insiders at NewAmsterdam Pharma Co N.V. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $1.3M 50,246 shares | -42% | |
| 38Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | Michael H. Davidson Chief Executive Officer | $227k 10,000 shares | +1% | |
| 26Weak | NAMSsell NewAmsterdam Pharma Co N.V. | John W Smither director | $41k 1,600 shares | -15% | |
| 14Weak | NewAmsterdam Pharma Co N.V. | ForGrowth NAP B.V. owner | $762k 29,846 shares | -0% | |
| 17Weak | NewAmsterdam Pharma Co N.V. | ForGrowth NAP B.V. owner | $1.9M 74,910 shares | -1% | |
| 17Weak | NewAmsterdam Pharma Co N.V. | ForGrowth NAP B.V. owner | $2.3M 91,068 shares | -1% | |
| 17Weak | NewAmsterdam Pharma Co N.V. | ForGrowth NAP B.V. owner | $4.1M 157,234 shares | -1% | |
| 17Weak | NewAmsterdam Pharma Co N.V. | ForGrowth NAP B.V. owner | $3.0M 115,480 shares | -1% | |
| 17Weak | NewAmsterdam Pharma Co N.V. | ForGrowth NAP B.V. owner | $4.9M 191,762 shares | -2% | |
| 17Weak | NewAmsterdam Pharma Co N.V. | ForGrowth NAP B.V. owner | $12M 462,288 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.